1. Generics Bulletin
  2. >>Products
  3. >>Generics

Glenmark Debuts Favipiravir For COVID-19 In India

Poised For Scale-Up Using In-House Capabilities

 
• By Anju Ghangurde

Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process. While the firm says trial findings are in line with global data, with patients showing clinical improvements within the first seven days, social media is abuzz, with some physicians seeking greater clarity.

Coronavirus COVID-19 medical test vaccine research and development concept. Scientist in laboratory study and analyze scientific sample of Coronavirus antibody to produce drug treatment for COVID-19.
Favipiravir Gets India Green Light After Accelerated Approval • Source: Shutterstock

Glenmark Pharmaceuticals appears to have stolen a march over its peers after it received regulatory clearance in India for and launched its version of favipiravir, the antiviral currently being evaluated as part of treatment options for COVID-19 in several countries including Japan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products